New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
07:10 EDTGSK, ISISIsis Pharmaceuticals earns $1M from GlaxoSmithKline for advancing ISIS-TTR Rx
Isis Pharmaceuticals (ISIS) announced that it has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the initiation of an open-label extension study of ISIS-TTR, which is being offered to those patients with familial amyloid polyneuropathy who have completed dosing in the Phase 2/3 study of ISIS-TTR. ISIS-TTR is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis. Including this milestone payment, Isis has earned $25M in upfront and milestone payments for advancing ISIS-TTRRx. This $1M milestone payment is the third of the $50M in milestone payments Isis is eligible to earn as the Phase 2/3 study progresses.
News For ISIS;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
09:21 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:15 EDTGSKAgenus reports GSK ZOE-50 Phase 3 study met primary endpoint
Subscribe for More Information
December 16, 2014
07:06 EDTISISIsis Pharmaceuticals initiates phase 1/2 study of ISIS-DMPK Rx
Subscribe for More Information
December 11, 2014
09:28 EDTISISIsis Pharmaceuticals up 3% after CEO appears on Mad Money
Subscribe for More Information
December 9, 2014
10:23 EDTGSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTGSKAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information
10:41 EDTISISIsis Pharmaceuticals price target raised to $81 from $62 at Piper Jaffray
Subscribe for More Information
08:00 EDTISISIsis Pharmaceuticals price target raised to $66 from $55 at Stifel
Subscribe for More Information
05:30 EDTISISIsis Pharmaceuticals to host conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use